Sera from 391 southern African Blacks with hepatocellular carcinoma, matched controls, patients with other malignant tumours, and with various forms of hepatobiliary disease were fractionated by polyacrylamide gradient gel electrophoresis to determine the prevalence of tumour-associated y-glutamyl transferase isoenzymes in Black patients with hepatocellular carcinoma. One or more tumour-associated isoenzymes (I', I" or II') were present in 58.6% of the patients with hepatocellular carcinoma: I' in 54.5%, I" in 27.1%, and II' in 34%. These isoenzymes were detected in one patient with prostatic cancer, occasionally in patients with acute viral hepatitis, but in no normal individuals. The presence of tumour-associated isoenzymes was not related to patient age, sex or hepatitis-B virus status or to the tumour burden. Isoenzymes were present in 42 percent of hepatocellular carcinoma patients with a normal serum a-foetoprotein concentration and in 50% of those with a non-diagnostic value. y-glutamyl transferase isoenzymes may be supplementary to a-foetoprotein in the diagnosis of hepatocellular carcinoma.
Gamma-glutamyl transferase (EC 2.3.2.2) (y-GT) activity is high in foetal liver (Albert et al., 1970; Fiala et al., 1972) , in experimental hepatocellular carcinoma (HCC) tissue (Fiala et al., 1972; Fiala & Fiala, 1973; Kalengayi et al., 1975) , and in the preneoplastic lesions which precede these tumours (Kalengayi et al., 1975; Ohmori et al., 1981) , but is low in adult liver tissue (Albert et al., 1970; Fiala et al., 1970) . This exact parallel in behaviour with a-foetoprotein (aFP), a known carcinoembryonic glycoprotein and a useful serum marker of human HCC (Kew & Newberne, 1982) , suggested that y-GT too might have carcinoembryonic characteristics, and that a foetal isoenzyme might be produced and secreted by human HCC tissue and serve as an additional marker of this tumour. Indeed, tumourassociated (or novel) isoenzymes of y-GT have recently been demonstrated in the serum of a proportion of Japanese patients with HCC (Kojima et al., 1980; Sawabu et al., 1983) . The purpose of the present study was to determine the frequency with which tumour-associated isoenzymes of y-GT occur in HCC in another population which has a high incidence of this tumour, namely southern African Blacks, and to assess the diagnostic value of these isoenzymes in comparison with cxFP.
Patients and methods
Sera from 391 southern African Blacks with histologically-proved HCC were fractionated by Correspondence: M.C. Kew polyacrylamide gradient gel electrophoresis to determine the prevalence of tumour-associated isoenzymes of y-GT. The patients studied ranged in age from 13 to 87 years with a mean age of 45.2 years. Males constituted 86.5% of the cohort studied. For the purpose of racial comparison, sera from 22 caucasian patients with HCC were also tested.
The following groups of subjects served as controls: 80 apparently healthy age-, sex-, and ethnically-matched individuals (including six in whom the serum was concentrated three-fold using polyethylene glycol); 46 patients with various malignant tumours other than HCC with or without hepatic metastases (arising from breast, stomach, lung, ovary, pancreas, cervix, kidney, prostrate, bladder, rectum or oesophagus; teratocarcinoma, cholangiocarcinoma); 32 patients with amoebic liver abscess; 22 patients with active chronic hepatitis or cirrhosis; 29 patients with acute viral hepatitis; and 28 patients with biliary obstruction.
Sera were separated and stored at -20°C until assayed. Electrophoretic separation of y-GT was performed on Pharmacia polyacrylamide gradient gel slabs (PAA4/30) using the Pharmacia Gel Electrophoresis Apparatus GE-2/4 LS (Pharmacia Fine Chemicals, Uppsala, Sweden) according to the method of Kojima et al. (1980) . The N-y-glutamyloa-naphthylamide used in the substrate mixture and the glycylglycine were obtained from Sigma Chemical Co., St Louis, Mo. The gels were stained with Fast Garnet GBC which was also obtained from the Sigma Chemical Co. The Pharmacia Fine Chemicals Electrophoresis Calibration Kit for determination of high mol wt proteins, containing albumin, lactic dehydrogenase, catalase, ferritin and thyroglobulin, together with bovine transferrin (Sigma Chemical Co.) was used as a basis of electrophoretic comparison after staining with Coomassie Brilliant Blue R-250.
In sera from normal individuals up to 10 y-GT fractions (I-X) are obtained. The electrophoretic mobility of fraction I is comparable to transferrin, that of fraction II to lactic dehydrogenase, that of fraction III to catalase, that of fraction V to ferritin, and that of fraction VIII to thyroglobulin. The purified proteins used as markers have no y-GT activity. Three tumour-associated (or novel) fractions have been described in patients with HCC: these are labelled I', I" and II' by Kojima et al. (1980) . Fraction I' migrates slightly slower than fraction I, fraction I" slightly faster than fraction II, and fraction II' bewteen fractions II and III ( Figure  1 ).
The serum concentration of y-GT was determined in the HCC patients on a Multistat III centrifugal analyser using the Boehringer Mannheim Kit. No. 125954 with L-y-glutamyl-3-carboxy-4-nitroanilide as the substrate. The enzyme activity was expressed in international units per litre of serum at 37°C. Serum aFP concentrations in the HCC patients were measured by double-antibody radioimmunoassay (Amersham Corp., Arlington Heights, Ill.). The HCC patients' sera were also tested for hepatitis-B virus surface antigen (HBsAg) using a double-antibody radioimmunoassay (Ausria II; Abbott Laboratories, North Chicago, Ill.).
The statistical validity of the findings was tested using either the Chi square test with Yates' modification for small numbers or an unpaired Students' t test. The isoenzymes which may be present in normal serum or in patients with benign hepatobiliary disease are indicated by the small Greek numerals I to X; the position of the 3 tumour-associated isoenzymes is also shown. A. Normal human serum. B-F. Serum from patients with hepatocellular carcinoma showing various combinations of the 3 tumour-specific isoenzymes (in addition to normal fractions in some patients).
Results

Hepatocellular carcinoma patients
Fraction I' was detected in 54.5% (213/391) of the HCC patients, fraction I" in 27.1% (106/391), and fraction II' in 34.0% (133/391). One or more of the three tumour-associated isoenzymes was detected in 58.6% (229/391) of the HCC patients. The prevalence of the various combinations of the tumour-associated isoenzymes is shown in Table I . Fraction I' was the most frequent of the single fractions (75/86), and the simultaneous presence of I', I" and II" among the combined patterns (80/143).
Controls
Tumour-associated isoenzymes were not detected in any of the 80 healthy controls, including the six in whom the serum was concentrated, or in any of the 32 patients with amoebic liver abscess, the 28 with biliary obstruction, or the 22 patients with chronic active hepatitis or cirrhosis. One or more tumourassociated fractions were occasionally found in the other control groups (Table I ). The one patient with malignant disease to show these isoenzymes had prostatic cancer complicated by skeletal but not hepatic metastases.
Correlation with sex, age and race
Sex
The presence of tumour-associated y-GT isoenzymes was not related to the sex of the patients with HCC, males constituting 88.7% of the patients with, and 83.3% of those without these isoenzymes. There was also no difference with regard to sex between patients having I', I" or II' fractions, males constituting 88.8% of patients with I' and I" and 87.3% of those with II'.
Age
There was no correlation between the presence of tumour-associated y-GT isoenzymes and patient age. The mean age (and s.d.) of the patients with these isoenzymes was 44.6 + 14.7 years (range 17-87) and those without isoenzymes 46.4+15.5 years (range 13-78 years). Nor was there any difference between the ages of the patients with I', I" or Relationship between y-GT isoenzymes and y-GT Serum y-GT levels were raised (>50 U1in normal men and 35Ul-1 in normal women) in 95% (359/378) of the HCC patients; values ranged up to 1617 UI -1. HCC patients with one or more tumour-associated isoenzymes were more likely to have a raised serum y-GT value (99.1%; 221/223) than those without isoenzymes (89.0%; 138/155; P<0.001). Patients having all 3 isoenzymes invariably had a raised serum y-GT concentration. There was no difference in the percentage of patients with an elevated y-GT level between those with I' (99.5%), I" (100%) and II' (99.2%). The mean serum y-GT concentration was significantly higher (346 + 220 UI 1) in patients with than in those without (261+228UP-1) (P<0.0005) tumourassociated y-GT isoenzymes. There was no significant difference between the serum values of patients having all 3 isoenzymes and those having one or two isoenzymes. Nor was there any difference between those having I' (351 + 223 Ul 1), I" (357+186 Ul-1) or II'(349+ 187 Ul-1). Of the 33 patients with a normnal serum aFP value, tumour-associated y-GT isoenzymes were detected in 14 (42.4%). In practice, therefore, if serum from patients with HCC was tested for both AFP and y-GT isoenzymes 95.2% of the patients would have a marker of HCC (either a raised serum a-FP value or a tumour-associated isoenzyme of y-GT) whereas 91.6% of the patients would have a marker (raised serum aIFP level) if y-GT isoenzymes were not measured. Of the 66 patients in the non-diagnostic cxFP range (10-500ngml-1) 33 (50.0%) had one or more y-GT isoenzymes. In practice, if y-GT isoenzymes were used together with aFP determination in the diagnosis of HCC, it would then be possible to reduce the number of patients with a nondiagnostic aFP value from 16.9 to 8.4% i.e. only 8.4% of the patients would have neither an isoenzyme of y-GT nor a diagnostic level of aFP and hence no marker of HCC.
Relation between y-GT isoenzymes and HBsAg
No correlation could be demonstrated between the presence of tumour-associated y-GT isoenzymes and HBsAg, 46.5% (101/217) of the patients with one or more isoenzymes and 42.0% (58/138) of those without isoenzymes being HBsAg-positive. There was no difference between patients with I', I" and II' in respect to 47.0 and 44.0% respectively).
Relation between y-GT isoenzymes and tumour burden
No correlation could be demonstrated between the presence of tumour-associated y-GT isoenzymes and the extent of the tumour burden (tumour size as judged by isotopic, ultrasonographic or computed tomographic imaging techniques, and extent of metastatic spread) in individual patients. These enzymes are of no particular value in the detection of small (and hence resectable) tumours.
Discussion
Although aFP is a most useful marker of HCC, both "false-negative" and "false-positive" results occur (Kew & Newberne, 1982) . Even with a very senstitive radioimmunoassay, approximately 8% of patients in high incidence areas of the tumour have values in the normal range, and in low incidence regions this figure may be as high as 30%. Slightly raised serum values (up to 500ngml-1) occur in various forms of benign liver disease including acute hepatitis, active chronic hepatitis and cirrhosis. Elevetated levels may also be seen with tumours of entodermal origin and the rare embryonal teratocarcinomas of gonadal origin. Alternative or additional markers having no 'falsenegative' or 'false-positive' results or else being present when xFP is either normal or is present in the non-diagnostic range, are still being sought. Studies in Japanese patients have suggested that novel 'tumour-associated' isoenzymes of y-GT might serve as a marker of HCC (Kojima et al., 1980; Sawabu et al., 1983) .
The present investigation has shown a virtually identical prevalence of tumour-associated y-GT isoenzymes in another population with a high incidence of HCC but differing in several respects from Japanese patients, namely southern African Blacks. The prevalence of tumour-associated y-GT isoenzymes has not yet been documented in any population with a low incidence of HCC. A comparison between Black and Caucasian patients was therefore attempted in the present study. Although the prevalence of the isoenzymes was less in Caucasian patients, the number of the latter was small and the differences did not reach statistical significance.
Tumour-associated y-GT isoenzymes are not present sufficiently often in patients with HCC for them to be superior to aFP as a marker of this tumour. However, they might still be useful diagnostically if they were detected in patients having a normal cxFP value or one in the nondiagnostic range. Unfortunately, the isoenzymes tended to have a directly proportional rather than an inversely proportional relationship with aFP: y-GT isoenzymes were present in less than one-half of the patients with normal or non-diagnostic cxFP values. Nevertheless, they may be of some diagno' ic value when used in conjunction with cxFP estimation. Unlike aFP, which is related to both the age and the sex of HCC patients (Kew & Newberne, 1982) , y-GT isoenzymes were not ageor sex-related. It might be argued, therefore, that y-GT isoenzymes may be somewhat more useful diagnostically in elderly patients, especially females, in whom aFP is less likely to be elevated. y-GT isoenzymes were also not related to the aetiology of the tumour, insofar that they did not correlate with the presence or absence of HBs antigenemia. y-GT isoenzymes are also of no particular value in the early diagnosis of HCC.
The serum y-GT concentration was raised in 95% of our patients. Tumour-associated isoenzymes were shown to contribute to the serum value in that patients with one or more of these isoenzymes had significantly higher levels. However, other factors also play a role because the serum values were raised even in the absence of the isonzymes. Only 1% of patients with tumourassociated y-GT isoenzymes had a normal serum y-GT value. In practice, therefore, tumour-associated isoenzymes are very unlikely to be present in patients with HCC if the serum y-GT concentration is not raised.
Although tumour-associated y-GT isoenzymes were not found in healthy Blacks (nor previously in healthy Japanese (Kojima et al., 1980) ), they were present in a single patient with malignant disease, and in three patients with acute viral hepatitis. y-GT is normally present in many tissues but particularly the pancreas and kidney (Albert et al., 1961) , and it is therefore not surprising that tumour-associated isoenzymes are occasionally encountered in patients with various forms of malignancy (Jaken & Mason, 1978) . The enzyme is present in prostatic tissue (Albert et al., 1964; Rosalki & Rowe, 1973) , which would explain the single patient who belonged in this category in our series who had a prostatic carcinoma. The finding of tumour-associated bands in an occasional patient with acute hepatitis by ourselves and by Kojima et al. (1980) or chronic hepatic parenchymal disease by the latter workers is less easy to explain. There is, however, an analogy with the raised levels of aFP which may occur in the same conditions. The latter has been attributed to production of aiFP by regenerating hepatocytes (Kew & Newberne, 1982) , and perhaps the same applies to y-GT isoenzymes.
One explanation for the difference in electrophoretic mobility of the tumour-associated y-GT isoenzymes is that they may result from differences in sialic acid content. A sialic acid-rich foetal type y-GT has been detected in undifferentiated cryptal cells, and in the foetal small intestine and liver (Knottgen et al., 1976) . This suggests that y-GT, like acFP, has carcinoembryonic characteristics. An alternative explanation for the tumour-associated bands is that they are formed artifactually by combining with lipoprotein or glycoprotein in the serum (Freise et al., 1976) .
